Table 2.

List of compounds used in Phase II trials (randomized and single-arm trials), divided by main classes of drugs

Chemotherapy	Targeted agents		Immunotherapy	Cellular therapy
	Tyrosine kinase inhibitors (TKIs)	Other
13‐Deoxy, 5‐iminodoxorubicin (GPX‐150) Aldoxorubicin Amrubicin Bendamustin Brostallicin Dacarbazine Docetaxel Doxorubicin Eribulin Evofosfamide Exatecan Gemcatabine Ifosfamide Ixabepilone Liposomal doxorubicin Lurbinectedin Non-pegylated liposomal doxorubicin Paclitaxel Pemetrexed Plitidepsin Soblidotin Thalidomide Trabectedin Trofosfamide	Alisertib Anlotynib Axitinib Brivanib Cediranib Crizotinib Dasatinib ENMD-2076 Gefitinib Pazopanib Regorafenib Sorafenib Sunitinib Tivozanib	Aflibercept Bevacizumab Conatumumab Ganetespib Letrozole Olaratumab Ontuxizumab Palbociclib Panobinbostat Perifosine Ridaforolimus Selumetinib Sirolimus Tazemetostant Temsirolimus Thrombospondin-1-Mimetic Angiogenesis Inhibitor ABT-510 Trebananib Vorinostat	Nivolumab Pembrolizumab Talimogene laherparepvec (T-VEC)	NY-ESO-1c259T Cells